Loss in match with the previous quarter. ARS Pharmaceuticals Inc. (NASDAQ: SPRY) reported a loss of $0.42 per share for Q4 2025, matching the prior quarter’s loss of $0.42 per share but swinging from a profit of $0.51 per share in the year-ago period. The 182% year-over-year decline marks a dramatic reversal for the biotechnology company, which posted its first profitable quarter a year ago. The company recorded a net loss of $41.3 million for the quarter.
Revenue surges despite profitability pressure. Revenue reached $28.1 million, down 13.5% from the prior quarter’s $32.5 million but up 332% from $6.5 million in Q4 2024. The sequential decline follows a strong Q3 2025 that saw revenue peak at $32.5 million, suggesting potential volatility in commercial uptake. The company held its earnings call at 8:30 AM ET on March 9 to discuss the results. Trading volume reached 1.5 million shares as the stock traded at $9.12, well below its 52-week high of $18.90.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post ARS Pharmaceuticals (SPRY) Posts Q4 Loss of $0.42/Share as Revenue Jumps 332% YoY to $28.1M first appeared on test.
